CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25979925.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2556.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.
Medical subject headings
- Hematologic Neoplasms
- Histone Deacetylase Inhibitors
- Hydroxamic Acids